Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Weiss, TW; Aichinger, J; Huber, K; Speidl, WS; Watzinger, N; Zweiker, R; Alber, HF.
Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.
Wien Klin Wochenschr. 2016; 128(11-12):450-457 Doi: 10.1007/s00508-016-1016-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz

Zweiker Robert

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

The protective effect of dual antiplatelet therapy (DAPT) following acute coronary syndrome is undisputed, but its duration is subject of debate. Several studies show that prolonged therapy provides a clinical benefit in patients following acute coronary syndrome. The aim of this position paper authored by Austrian experts is to outline the current evidence and provide an overview of recent studies. It is also intended to serve as a practical guide to identify those patients who may benefit from prolonged DAPT.

Find related publications in this database (using NLM MeSH Indexing)

Aspirin - administration & dosage

Aspirin - standards

Austria -

Drug Administration Schedule -

Evidence-Based Medicine - standards

Humans -

Myocardial Infarction - drug therapy

Myocardial Infarction - prevention & control

Platelet Aggregation Inhibitors - administration & dosage

Platelet Aggregation Inhibitors - standards

Practice Guidelines as Topic -

Purinergic P2Y Receptor Antagonists - administration & dosage

Purinergic P2Y Receptor Antagonists - standards

Secondary Prevention - standards

Treatment Outcome -

Find related publications in this database (Keywords)

P2Y(12) inhibitor

Acute coronary syndrome

DAPT

Myocardial infarction

Ticagrelor

© Med Uni Graz • Impressum